The new approach for Neurofibromatosis type 1 treatment using TNF-alpha antibody
Project/Area Number |
23791253
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Dermatology
|
Research Institution | Saitama Medical University (2013) University of Tsukuba (2011-2012) |
Principal Investigator |
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 神経線維腫症1型 / 神経線維腫 / TNF-alpha / 神経線維腫症 |
Research Abstract |
The patients with neurofibromatosis type 1 (NF-1) have multiple cutaneous neurofibroma and some neurofibroma may increase in huge size and develop malignant peripheral nerve sheath tumor, which harm patients' quality of life and lead to the dismal vital prognosis. The investigator confirmed that the tumor necrosis factor alpha (TNF-alpha) augments mitogenic activity of cultured human neurofibroma cells. In this study, the growth responses of in vivo neurofibroma to TNF-alpha was invastigated. the tumor growth in the group of NF-1 modelmouse who was given TNF-alpha was stronger than that in the group NF-1 mouse without TNF-alpha administration. Inhibition of the TNF-alpha action with specific TNF-alpha antibody led to the tendency of suppression of neurofibroma growth in NF-1 modelmouse.
|
Report
(4 results)
Research Products
(45 results)